MoonLake Immunotherapeutics
NASDAQ:MLTX
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
36.67
63.86
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MLTX stock under the Base Case scenario is 7.72 USD. Compared to the current market price of 51.78 USD, MoonLake Immunotherapeutics is Overvalued by 85%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
MoonLake Immunotherapeutics
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MLTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
MoonLake Immunotherapeutics
Balance Sheet Decomposition
MoonLake Immunotherapeutics
Current Assets | 536.9m |
Cash & Short-Term Investments | 519.8m |
Receivables | 16.2m |
Other Current Assets | 918.6k |
Non-Current Assets | 8m |
PP&E | 3.9m |
Other Non-Current Assets | 4.1m |
Current Liabilities | 12.3m |
Accounts Payable | 4.9m |
Accrued Liabilities | 7.1m |
Other Current Liabilities | 232.4k |
Non-Current Liabilities | 11.9m |
Other Non-Current Liabilities | 11.9m |
Earnings Waterfall
MoonLake Immunotherapeutics
Revenue
|
0
USD
|
Operating Expenses
|
-78.4m
USD
|
Operating Income
|
-78.4m
USD
|
Other Expenses
|
23.6m
USD
|
Net Income
|
-54.8m
USD
|
Free Cash Flow Analysis
MoonLake Immunotherapeutics
USD | |
Free Cash Flow | USD |
MLTX Profitability Score
Profitability Due Diligence
MoonLake Immunotherapeutics's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
Score
MoonLake Immunotherapeutics's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
MLTX Solvency Score
Solvency Due Diligence
MoonLake Immunotherapeutics's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
MoonLake Immunotherapeutics's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MLTX Price Targets Summary
MoonLake Immunotherapeutics
According to Wall Street analysts, the average 1-year price target for MLTX is 74.31 USD with a low forecast of 40.4 USD and a high forecast of 109.2 USD.
Dividends
Current shareholder yield for MLTX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
MoonLake Immunotherapeutics is a CH-based company operating in industry. The company is headquartered in Zug, Zug. The company went IPO on 2020-10-20. MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Contact
IPO
Employees
Officers
The intrinsic value of one MLTX stock under the Base Case scenario is 7.72 USD.
Compared to the current market price of 51.78 USD, MoonLake Immunotherapeutics is Overvalued by 85%.